Anixa Biosciences Secures Australian Patent for Breast Cancer Vaccine

The newly accepted patent, titled Vaccine Adjuvants and Formulations, was developed at the Cleveland Clinic and exclusively licensed to the San Jose-based company. It joins a growing list of protections already secured in the United States, Japan, China, and across Europe. For Anixa, the move is a preparatory step toward potential regulatory approval and future commercial partnerships outside the U.S. market.

This technology targets human α-lactalbumin, a protein typically associated with lactation that appears in certain aggressive breast cancers, including triple-negative variants. By utilizing a retired protein strategy, the vaccine aims to prime the immune system to prevent tumor formation without damaging healthy tissue. Recent Phase 1 trial data, funded by the U.S. Department of Defense, showed the vaccine met primary safety endpoints and generated immune responses in over 74% of participants. Dr. Amit Kumar, Chairman and CEO of Anixa, noted that this international recognition validates the platform’s potential as the company seeks to address the rising global incidence of breast cancer.